SCHEMBL1813640

SCHEMBL1813640

Cc1cc(C(O)(c2ccccc2)C(F)(F)F)cc(C)c1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 4/20 0.43
POLB P06746 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 2/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
NR1I2 O75469 1/20 0.38
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
ALDH1A1 P00352 3/20 0.35
TSHR P16473 2/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
NR1H3 Q13133 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3137760 0.84 NR3C1 (0.44) NR1H2POLBSMN1; SMN2ALDH1A1TSHR
SCHEMBL2265629 0.81 NR1H2 (0.39) NR1H2POLBSMN1; SMN2KDM4EMEN1
SCHEMBL5865852 0.80 TSHR (0.52) NR1H2MAPTNR1I2LMNAMAPK1
SCHEMBL1815767 0.77 NR1H2 (0.47) NR1H2NR1I2MAPK1ALDH1A1TSHR
SCHEMBL5865830 0.77 NR1H2 (0.51) NR1H2POLBSMN1; SMN2MEN1KMT2A
SCHEMBL3420846 0.77 NR1H2 (0.43) NR1H2POLBMEN1MAPTKMT2A
SCHEMBL1812445 0.76 TDP1 (0.44) NR1H2MAPTNR1I2LMNAALDH1A1
Hydrochloric Acid SCHEMBL18275180 0.76 NR1H2 (0.46) NR1H2NR1I2MAPK1ALDH1A1TSHR
SCHEMBL4612449 0.73 MEN1 (0.46) NR1H2MEN1MAPTKMT2ANR1I2
SCHEMBL1812412 0.73 NR1H2 (0.43) NR1H2NR1I2LMNAESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201603-A1 Novel Acylaminobenzamide Derivatives BAYER CROPSCIENCE AG (DE) 2011-08-18 US disclosed
EP-2318358-A2 ACYLAMINOBENZAMIDE DERIVATIVES Bayer CropScience AG (DE) 2011-05-11 EP disclosed
WO-2010015355-A2 NOVEL ACYLAMINOBENZAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201603-A1 Novel Acylaminobenzamide Derivatives KCNB1, KCNA5, KCNA7 NR1H2 3059/4885POLB 1730/4885SMN1; SMN2 4532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.